|

Upadacitinib Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: ABT-494, ATC 200000041628, RINVOQ, Rinvoq

Pipeline

Phase 3: 2

Top Sponsors

  • AbbVie2
  • Universidade do Porto1

Indications

  • Arthritis2
  • Adverse Drug Reaction1
  • Drug Side Effect1
  • Juvenile Idiopathic Arthritis1
  • Systemic Lupus Erythematosus1

Other1 trial

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

Chandler, Arizona1 trial

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

AZ Arthritis and Rheumatology /ID# 261848

Phase 3

Phoenix, Arizona1 trial

Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.

Phoenix Children's Hospital /ID# 253403

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.